Media-Kangpu Biopharmaceuticals

　　　

English 简体中文

Company Profile

Our Culture

Leadership

Honors
Technology

Pipeline

Clinical Trials

Diseases
Media
Investors
Careers
Contact

868 Sichuan Road, Suite 401, Building B1, Yungu Innovation Park, Baohe District, Hefei, Anhui Province, China

Email: info@KangpuGroup.com

© Copyright Kangpu Biopharmaceuticals. All rights reserved.

Forward Looking Statements|Privacy Policy|Terms of Use|Site Map

Home / Media

Media

Media

Oct 21, 2024

Kangpu Announces Upcoming Presentation and Participation at the 7th Annual TPD & Induced Proximity Summit in Boston
Learn More
Sep 20, 2024

Kangpu Completed Bridging Clinical Study of KPG-818 in China
Learn More
Jun 11, 2024

Kangpu Biopharmaceuticals to Present Results from Phase 2a of KPG-818 in SLE at EULAR 2024
Learn More
Jun 05, 2024

FDA Approved Phase II/III Clinical Study of KPG-121 in Combination with Abiraterone as a First Line Treatment for mCRPC
Learn More
Feb 19, 2024

Kangpu Biopharmaceuticals to Present Preclinical Efficacy Data of KPG-818 in Crohn's Disease at the 19th Congress of ECCO (IND Application for Phase II in Progress)
Learn More
Oct 27, 2023

Kangpu To Present a Case Report of KPG-121 in Combination with Enzalutamide for the Treatment of mCRPC at SITC 2023
Learn More
Mar 20, 2023

Kangpu Completes Patient Enrollment for Phase IIa Clinical Trial of KPG-818 in SLE in the US
Learn More
Nov 25, 2022

Kangpu Presented Phase Ib Results of KPG-818 in SLE at ACR Convergence 2022
Learn More
Jun 13, 2022

Kangpu Announces First Patient Dosed in the US Phase IIa Clinical Trial of NeoMIDES™ Molecular Glue KPG-818 in Systemic Lupus Erythematosus
Learn More
Nov 16, 2020

Kangpu Biopharmaceuticals Initiates Phase Ib/IIa Clinical Trial of KPG-818 in Systemic Lupus Erythematosus
Learn More

1 2

为了更好的呈现效果，移动端请竖屏浏览